Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
SPCX is caught in an uncomfortable split: the stock has shed nearly 9% in five sessions to $156.54, yet the bears who should be benefiting keep closing their positions. That disconnect, between a falling stock and a shrinking short book, is the defining tension heading into the November 5 earnings date.
The short retreat is now a sustained trend, not a blip. Estimated shares short fell to 172.8 million on October 13, down 3.8% on the week and continuing a pullback that started from the September 24 peak of 195.4 million. The ORTEX short score has eased to 51.6, the lowest reading in the past two weeks and down meaningfully from the 55 range that held through late September and early October. The borrow market offers no signs of stress either. Cost to borrow is a modest 0.57%, up only fractionally on the week, and availability has actually loosened to 227%, meaning there are more than two shares available to lend for every one currently shorted. The 52-week low for availability was near zero; the current reading is nowhere close to tight. Shorts are not being squeezed out. They are choosing to leave.
Options positioning is calm and close to neutral. The put/call ratio of 1.00 is a fraction below its 20-day average of 1.02, and the z-score of minus 0.53 signals nothing unusual in either direction. There is no sign of option traders loading up on downside protection despite the weekly drop, which argues against a panicked investor base, but also against any surge of conviction from the bull side.
The Street remains firmly positive despite the price weakness. Barclays initiated coverage last Thursday with an Overweight rating and a $254 target, the most bullish stance on the board. TD Cowen reiterated its Buy with a $200 target on the same day. Susquehanna raised its Neutral target to $173 from $144 earlier in the week, acknowledging the stock's post-IPO progress while stopping short of conviction. The mean price target across analysts is $221, implying roughly 41% upside from the current $156.54 close. Bulls point to Starlink's cash generation potential, with connectivity revenue estimated at $17 billion in 2026 growing toward $85 billion by 2031, alongside emerging AI infrastructure revenue that analysts project rising from $19.4 billion in 2026 to $79.5 billion in 2027. Bears counter that Starship must scale to more than 1,000 launches per year to justify those numbers, and that the AI segment's second-quarter ad revenue fell roughly 14% year-on-year, casting doubt on the monetization timeline. Valuation reflects the ambiguity: the stock trades at 100.6 times trailing earnings, down from 118.6 thirty days ago as the share price has retreated but still a multiple that prices in a great deal of execution.
Ownership is heavily concentrated and unlikely to be a near-term catalyst. Elon Musk holds 44.7% of shares as last reported. Alphabet holds 4.1%, Google LLC filed a 13G disclosing 7.2% of class in August, and Peter Thiel's Founders Fund sits at 3.1%. None of the 13D/G filers have activist designation. All stakes are as-last-disclosed around the 5% threshold, and any holder dropping below 5% may not file again. The dominant feature of the register is its illiquidity at the top, which concentrates price discovery in a relatively thin public float.
The previous earnings print on August 5 produced an 8.3% single-day decline followed by a 16.6% gain over the following five sessions, a pattern that rewards patience over immediacy. The print before that showed the identical profile: down sharply on the day, sharply higher within a week. With November 5 now 22 days away, whether that pattern holds is what positions taken at current prices are ultimately betting on.
See the live data behind this article on ORTEX.
Open SPCX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
